Question explored with the scientific record
What is the optimal BP range for a 70 year old male with Hypertension Atrial Fibrillation and a history of of renal artery stenosis
The evidence for this exact patient is thin, but the best available data points to a systolic target around 130-140 mmHg, not lower.
The most directly relevant study is a 2014 analysis of the AFFIRM trial, which looked at blood pressure and outcomes in 3,947 patients with atrial fibrillation [1]. It found a U-shaped relationship: the lowest risk of death was at a systolic pressure around 140 mmHg and a diastolic around 78 mmHg [1]. Going below 110 mmHg systolic raised the risk of death nearly fourfold (hazard ratio 3.9), and going above 160 mmHg roughly doubled it [1]. This is a post-hoc analysis, not a randomized trial testing targets, so it is suggestive, not definitive.
Your patient's renal artery stenosis adds another layer. A 2017 meta-analysis of nondiabetic patients with chronic kidney disease found that intensive blood pressure control (targets below 130/80) did not slow kidney disease progression compared to standard control [4]. The annual rate of GFR decline was nearly identical between groups, and there was no difference in the risk of end-stage renal disease [4]. A 2019 meta-analysis of 20 trials found that intensive control reduced major cardiovascular events but had no significant effect on all-cause mortality, heart failure, or end-stage renal disease [2]. The benefit on events was concentrated in high-risk patients, not low-risk ones [3].
The evidence does not support pushing this man's systolic pressure below 120 mmHg. The AFFIRM data warns of harm below 110 mmHg [1], and the kidney data shows no renal benefit from aggressive targets [4]. A reasonable target is systolic 130-140 mmHg, with careful monitoring for orthostatic hypotension, especially given his age and the risk of falls from over-treatment [5].
My call: target systolic 130-140 mmHg, not lower. Confidence: moderate, because the evidence comes from post-hoc analyses and meta-analyses, not a trial designed for this exact combination of conditions.
Sources used 5
-
Optimal Blood Pressure in Patients With Atrial Fibrillation (from the AFFIRM Trial)
A post hoc AFFIRM trial analysis reveals a U-shaped relationship between average blood pressure and mortality/adverse outcomes in atrial fibrillation patients, with an optimal target around 140/78 mm Hg and increased risk when BP is lowered too much (<110/60 mm Hg).
DOI: 10.1016/j.amjcard.2014.06.002 -
Intensive versus Usual Control of Hypertension in the Prevention of Cardiovascular and Renal Outcomes: A Cumulative Meta-Analysis of Randomized Controlled Trials
In a cumulative meta-analysis of 20 RCTs (22 studies), intensive blood pressure control reduced MACEs and stroke but did not significantly affect mortality, heart failure, ESRD, or retinopathy overall; a subgroup suggested long-term ESRD benefit.
DOI: 10.1159/000499009 -
Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial
This study analyzes data from the SPRINT trial to determine the effects of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk, finding significant benefits for patients at high and intermediate risk but not for those at low risk.
DOI: 10.1177/2047487318800741 -
Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease
This systematic review and meta-analysis evaluates the effects of intensive blood pressure control compared to standard control on kidney disease progression in nondiabetic patients with chronic kidney disease, finding no significant differences in major renal outcomes but sugge…
DOI: 10.1001/jamainternmed.2017.0197 -
Syncope, Hypotension, and Falls in the Treatment of Hypertension: Results from the Randomized Clinical Systolic Blood Pressure Intervention Trial
Intensive SBP lowering to less than 120 mmHg increases risk of hypotension and possibly syncope, but does not increase falls, with no age-by-treatment interaction; older adults have higher absolute risk.
DOI: 10.1111/jgs.15236